Zisook S, Mendels J, Janowsky D, Feighner J, Lee J C, Fritz A
UCSD Department of Psychiatry.
Neuropsychobiology. 1987;17(3):133-8. doi: 10.1159/000118353.
Forty-two outpatients with major depressive disorder were treated with oral fezolamine in a 6-week, three-center open-label study. Therapy was initiated at 100 mg/day; thereafter dosage was increased based on the response of the patient. Maintenance dosage usually ranged between 100 and 450 mg/day. Clinically significant improvement relative to the patient's prestudy state was observed after 2 weeks in both patient and physician-rating scales. Fifty-five percent of patients improved their Hamilton Psychiatric Rating Scale for Depression (HAM-D) scores by more than 50%. The median dose associated with a clinically significant response was 245 mg/day. Five of the 6 patients who dropped out did so because of gastrointestinal adverse effects. The most common adverse effects were nausea (36%), headache (29%), constipation (26%), and dry mouth (24%).
在一项为期6周的三中心开放标签研究中，42名重度抑郁症门诊患者接受了口服非唑拉明治疗。治疗起始剂量为100毫克/天；此后根据患者反应增加剂量。维持剂量通常在100至450毫克/天之间。在患者和医生评定量表中，2周后均观察到相对于患者研究前状态有临床显著改善。55%的患者汉密尔顿抑郁量表（HAM-D）得分改善超过50%。与临床显著反应相关的中位剂量为245毫克/天。6名退出的患者中有5名是因为胃肠道不良反应。最常见的不良反应是恶心（36%）、头痛（29%）、便秘（26%）和口干（24%）。
